Literature DB >> 18698156

Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer.

Sonia Mulero-Navarro1, Manel Esteller.   

Abstract

Changes in chromatin structure are an essential mechanism for gene regulation (transcription, replication, DNA repair and recombination). ATP-dependent chromatin-remodeling enzymes have previously been implicated in maintaining and regulating chromatin structure. These enzymes are divided into several groups including the SWI/SNF, ISWI and CHD families. Although the Chromodomain Helicase DNA-binding protein (CHD) family members are involved in key cellular processes, the disrupted regulation of their expression has not been fully assessed. An impairment of chromatin remodeling activity, mediated by promoter CpG island hypermethylation of the described candidate genes, could be key in cancer pathology. Herein, we examine the DNA methylation profiles of CHD family members (CHD1-9) in different tumor types. For all CHDs, CpG island hypermethylation was only observed at the CHD5 promoter in human cancer cell lines and primary tumors, particularly gliomas and colon and breast carcinomas. RT-qPCR analyses correlated CHD5 loss of expression with hypermethylation of the promoter, and restoration of CHD5 mRNA levels upon treatment with a DNA demethylating agent. These results underpin the epigenetic inactivation of the chromating remodeling factor CHD5 as one contributor for the aberrant structural changes of chromatin throughout the genome of the cancer cell.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18698156     DOI: 10.4161/epi.3.4.6610

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  38 in total

Review 1.  Epigenetic modifications and human disease.

Authors:  Anna Portela; Manel Esteller
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

2.  Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma.

Authors:  Didier Jean; Emilie Thomas; Elodie Manié; Annie Renier; Aurélien de Reynies; Céline Lecomte; Pascal Andujar; Jocelyne Fleury-Feith; Françoise Galateau-Sallé; Marco Giovannini; Jessica Zucman-Rossi; Marc-Henri Stern; Marie-Claude Jaurand
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 3.  Therapeutic targets for neuroblastomas.

Authors:  Garrett M Brodeur; Radhika Iyer; Jamie L Croucher; Tiangang Zhuang; Mayumi Higashi; Venkatadri Kolla
Journal:  Expert Opin Ther Targets       Date:  2014-01-06       Impact factor: 6.902

4.  The tumor suppressor Chd5 is induced during neuronal differentiation in the developing mouse brain.

Authors:  Assaf Vestin; Alea A Mills
Journal:  Gene Expr Patterns       Date:  2013-10-09       Impact factor: 1.224

5.  Array-based DNA methylation profiling of primary lymphomas of the central nervous system.

Authors:  Julia Richter; Ole Ammerpohl; José I Martín-Subero; Manuel Montesinos-Rongen; Marina Bibikova; Eliza Wickham-Garcia; Otmar D Wiestler; Martina Deckert; Reiner Siebert
Journal:  BMC Cancer       Date:  2009-12-21       Impact factor: 4.430

Review 6.  Architects of the genome: CHD dysfunction in cancer, developmental disorders and neurological syndromes.

Authors:  Wangzhi Li; Alea A Mills
Journal:  Epigenomics       Date:  2014       Impact factor: 4.778

7.  The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex.

Authors:  Venkatadri Kolla; Koumudi Naraparaju; Tiangang Zhuang; Mayumi Higashi; Sriharsha Kolla; Gerd A Blobel; Garrett M Brodeur
Journal:  Biochem J       Date:  2015-06-01       Impact factor: 3.857

Review 8.  The Chromodomain Helicase DNA-Binding Chromatin Remodelers: Family Traits that Protect from and Promote Cancer.

Authors:  Alea A Mills
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

9.  CHD5 is down-regulated through promoter hypermethylation in gastric cancer.

Authors:  Xian Wang; Kenneth K K Lau; Leo K Y So; Yun Wah Lam
Journal:  J Biomed Sci       Date:  2009-10-19       Impact factor: 8.410

10.  Chd5 requires PHD-mediated histone 3 binding for tumor suppression.

Authors:  Shilpi Paul; Alex Kuo; Thomas Schalch; Hannes Vogel; Leemor Joshua-Tor; W Richard McCombie; Or Gozani; Molly Hammell; Alea A Mills
Journal:  Cell Rep       Date:  2013-01-10       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.